Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • SDPA_Pet
    Senior Member
    • Apr 2013
    • 222

    Bbtools/BBmaps output questions

    Hello, I am using "stats.sh" command in BBtools to check my assembled metagenomes. I am looking for N50 and the largest contig. In my case, there is a line shows "Main genome contig N/L50: 7688/759" and "Max contig length: 5.905 KB". I know N50 and L50? What is N/L50 here? Does this mean N50 = 7688 and L50=759? Why my max contig length is shorter than N50? Is this possbile? (details see attached files)

    A C G T N IUPAC Other GC GC_stdev
    0.2126 0.2873 0.2874 0.2127 0.0000 0.0000 0.0000 0.5747 0.0976

    Main genome scaffold total: 19074
    Main genome contig total: 19074
    Main genome scaffold sequence total: 15.193 MB
    Main genome contig sequence total: 15.193 MB 0.000% gap
    Main genome scaffold N/L50: 7688/759
    Main genome contig N/L50: 7688/759
    Main genome scaffold N/L90: 16532/636
    Main genome contig N/L90: 16532/636
    Max scaffold length: 5.905 KB
    Max contig length: 5.905 KB
    Number of scaffolds > 50 KB: 0
    % main genome in scaffolds > 50 KB: 0.00%
    Attached Files
  • kmcarr
    Senior Member
    • May 2008
    • 1181

    #2
    Originally posted by SDPA_Pet View Post
    Does this mean N50 = 7688 and L50=759?
    Yes, that is what that means.
    Why my max contig length is shorter than N50? Is this possbile?
    Because Brian believes (and I agree with him, not that he requires any validation from me) the proper notation should be N50=number of contigs making 50% of your assembly and L50=length lower limit of contigs making up 50% of your assembly. So what stats.sh is telling you is that the largest 7,688 contigs account for 50% of your assembly length and those contigs are all ≥ 759bp.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    16 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    18 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    24 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    37 views
    0 reactions
    Last Post SEQadmin2  
    Working...